CA125 monoclonal antibodies – epitope specificity and matched pairs for immunoassays
Study of epitope specificity
Epitope specificity of XEMA CA125 monoclonal antibodies was determined by competitive binding to enzyme-labelled human single patient CA125 antigen.
Antigen: natural human CA125 (lot CA23) isolated from single patient ovarian tumour ascitic fluid; purification method did not include affinity binding to monoclonal antibodies.
Conjugate of human CA125 lot CA23 with HRPO enzyme (Faizyme, Lansdowne, RSA) was performed by perjodate method.
Antibodies:
1) workshop ISOBM TD1 (1996) monoclonals kindly provided by K.Nustad (University in Oslo, Norway);
2) purified mAbs of XEMA;
Purity of all antibody preparations estimated as >90% by SDS-PAGE. Preparations of diluted antibodies were made from stock solutions in equal concentrations – 20 ug/ml in EIA buffer (0.1M PBS containing Tween-20 and casein).
Preparation of antibody-coated microwells was made in alkaline carbonate buffer; the microwells were post-coated by casein, dried and stored for up to one month before use.
HRPO-labelled CA125 preparation (lot CA23-HRPO) was diluted 1:500 by EIA buffer.
Cross-inhibition of natural CA125 binding was performed as follows: 50 ul of EIA buffer (in control well) or diluted antibodies were placed onto each antibody-coated microplate followed by an equal volume of diluted CA23-HRPO. The microplates were incubated for 45’ at room temperature on shaking platform. After 5xfold washing with saline-Tween, 100 ul of substrate were added to each well. The enzymatic reaction was stopped by addition of 5% sulphuric acid. The optical density was measured in microplate reader; inhibition percentages (see table 1) were calculated by dividing the average OD in actual wells by the average OD in control wells.
| | K95 (A1) | K93 (A2) | K90 (B1) | X52 | X75 | X306 | X325 | Epitope group |
| X52 | 0 | 2 | 28 | 85 | 50 | 0 | 41 | B2 |
| X75 | 0 | 6 | 82 | 85 | 87 | 0 | 78 | B1 |
| X306 | 88 | 78 | 5 | 3 | 5 | 91 | 5 | A1 |
| X325 | 0 | 0 | 40 | 41 | 66 | 3 | 89 | B1 |
Table 1. Cross-inhibition of XEMA CA125 mAbs and reference mAbs from TD1 workshop.
Rows – liquid phase antibodies; columns – immobilized antibodies.
See explanation in text.
Recommended pairs for immunoassays
The results show that mAb X306 clearly belongs to A1 (OC125 like) epitope group; mAb X75 shows high homology to B1 (M11 like) group.
Recommended pairs for immunoassays are:
X306 solid X52-HRPO conjugate – HIGHEST signal
X325 solid X52-HRPO conjugate
X306 solid X325-HRPO conjugate.
Please note that mAb X306 may suffer from perjodate and thus may not be recommended for HRPO-labelling.
Application of XEMA CA125 for immunohistochemistry
Anti-CA125 mAbs can be used for IHC staining of cryostat or paraffin-embedded tissues
mAb X325 is recommended for this purpose (see the example picture below – mammary carcinoma)

Development of rapid test for CA125 (lateral flow)
Rapid test for mass screening for ovarian carcinoma may be constructed from XEMA anti-CA125 mAbs
In a table below, there is a summary of the co-operative development performed with HBI Inc., Republic of Korea
| | GOLD/TEST | X52 | X75 | X306 | X325 |
| Antibody | X52 | | | +++ | +++ |
| X75 | + | | + | + |
| X306 | + | + | | + |
| X325 | + | + | + | |
| AS226 | + | + | + | + |
Gold conjugation(X52) – Test dispense(X325) Pair is best